Boehringer Ingelheim microParts GmbH

+492319799-0

Contact

About Boehringer Ingelheim

Innovative drugs for humans and animals - the research-based pharmaceutical company Boehringer Ingelheim has stood for more than 130 years. Boehringer Ingelheim is one of the 20 leading companies in the industry and is still a family business. For the three divisions Human Pharmaceuticals, Animal Health and Biopharmaceutical Order Production, around 50,000 employees create value through innovation every day.

Product portfolio of Boehringer Ingelheim

Product portfolio

Show all

News about Boehringer Ingelheim

06-Jun-2024 | business & finance

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

QUANTRO Therapeutics, a Spin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R ...

Read news

28-Nov-2023 | business & finance

German pharma company acquires University of Basel start-up for 450 million Swiss francs

New technology uses living bacteria to fight cancer

Read news

26-Apr-2023 | research and development

Boehringer Ingelheim inaugurates largest European development centre for biotechnology

Investment of 350 million euros is Boehringer Ingelheim's largest single investment in Germany to date

Read news

07-Jul-2022 | business & finance

Three partners committed to combat AMR

Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Read news

29-Nov-2021 | business & finance

PRIME’s technology for the development of novel veterinary vaccines

Boehringer Ingelheim and Biotech Startup enter a strategic collaboration

Read news

02-Nov-2021 | manufacturing

Boehringer Ingelheim opens smart factory

High-tech tablet production facility will further speed the market launch of innovative drugs

Read news

21-Oct-2021 | research and development

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the ...

Read news

12-Jan-2021 | business & finance

Boehringer Ingelheim and Google Partner for Pharma R&D

Scientists from both companies will be breaking new ground in the application of quantum computing to molecular dynamics simulations

Read news

Show more news about Boehringer Ingelheim

Boehringer Ingelheim microParts GmbH

About Boehringer Ingelheim

Product portfolio of Boehringer Ingelheim

Product portfolio

BMG LABTECH GmbH

Hamamatsu Photonics Deutschland GmbH

Thermo Fisher Scientific GmbH

Bruker Nano GmbH

News about Boehringer Ingelheim

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

German pharma company acquires University of Basel start-up for 450 million Swiss francs

Boehringer Ingelheim inaugurates largest European development centre for biotechnology

Three partners committed to combat AMR

PRIME’s technology for the development of novel veterinary vaccines

Boehringer Ingelheim opens smart factory

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Boehringer Ingelheim and Google Partner for Pharma R&D

Here you will find Boehringer Ingelheim microParts GmbH